Abstract: Polynucleotide expression constructs, populations of cells and methods of treating diseases caused by dysfunction in, or damage to, excitable tissues are provided.

Abstract: A method and device featuring at least one component providing a potential to kinetic converted elastic, magnetic repulsion, or, an elastic and magnetic repulsion, pushing, pulling, or, pulling and pushing, type of radially outward expansive force or pressure to an inner, outer, intermediate, and, combination thereof, wall region of the left ventricle, for reducing intraluminal hydrostatic pressure of the left ventricle (LV filling pressure) during the ventricular diastolic stage of the cardiac cycle, thereby, improving diastolic function of the left ventricle of the heart in subjects having a condition of diastolic heart failure (DHF), while minimally disturbing systolic function of the heart. The expansive force or pressure is in a range of about 5-40 mm Hg, whereby, left ventricular end diastolic pressure (LVEDP) is reduced down to the normal range of about 6-12 mm Hg, during ventricular diastole of the heart.

Abstract: An isolated polypeptide comprising, contiguously, a first amino acid sequence being at least 90% homologous to amino acid coordinates 1-398 of SEQ ID NO: 2, a tryptophan residue and a second amino acid sequence being at least 90% homologous to amino acid coordinates 400-523 of SEQ ID NO: 2. Also provided are polynucleotide sequences encoding this polypeptide and uses of same in the treatment of medical conditions associated with ion channel insufficiency.

Abstract: The present invention provides a system for improving diastolic function of the heart comprising elastic elements and attachment elements, wherein said elastic elements and said attachment elements are configured such that they are capable of being interconnected to form a chain formed of an alternating series of said elastic elements and said attachment elements, and wherein said attachment elements are adapted to be anchored in the wall of the heart and with option for drug delivery to the wall of the heart. The invention further provides devices, methods and kits, for mounting the ventricular function assisting device of the invention.

Abstract: A method of treating schizophrenia in a subject in need thereof is provided. The method comprising, administering to the subject a therapeutically effective amount of cells expressing at least one exogenous polypeptide forming a connexin channel and/or a hyperpolarizing ion channel, thereby treating the schizophrenia in the subject.

Abstract: Polynucleotide expression constructs, populations of cells and methods of treating diseases caused by dysfunction in, or damage to, excitable tissues are provided.

Abstract: A method for stretching at least a portion of an organ to decrease interstitial hydrostatic pressure and improve at least one organ function. The method comprises providing at least one elastically compressible anchor, compressing the at least one anchor, anchoring the at least one anchor to a portion of an organ from the group of organs consisting of: a kidney, a liver, a bladder, and a stomach. The method further comprises releasing the compressing, thereby stretching the portion and decreasing interstitial hydrostatic pressure.

Abstract: Polynucleotide expression constructs, populations of cells and methods of treating diseases caused by dysfunction in, or damage to, excitable tissues are provided.

Abstract: A method of treating a movement disorder in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of cells capable of modifying a neuronal discharge of the subject, thereby treating the movement disorder in the subject, wherein said administering is effected at a site selected from the group consisting of internal globus pallidus, subthalamic nucleus and substantia nigra pars reticulate.

Abstract: A method of modifying the electrophysiological function of an excitable tissue region of an individual is provided. The method includes the step of implanting cells into the excitable tissue region. Each implanted cell is (a) capable of forming gap junctions with at least one cell of the excitable tissue region; and (b) capable of forming a functional ion channel or transporter, wherein the functional ion channel or transporter is capable of modifying the electrophysiological function of the excitable tissue region.

Abstract: A method and device featuring at least one component providing a potential to kinetic converted elastic, magnetic repulsion, or, an elastic and magnetic repulsion, pushing, pulling, or, pulling and pushing, type of radially outward expansive force or pressure to an inner, outer, intermediate, and, combination thereof, wall region of the left ventricle, for reducing intraluminal hydrostatic pressure of the left ventricle (LV filling pressure) during the ventricular diastolic stage of the cardiac cycle, thereby, improving diastolic function of the left ventricle of the heart in subjects having a condition of diastolic heart failure (DHF), while minimally disturbing systolic function of the heart. The expansive force or pressure is in a range of about 5–40 mm Hg, whereby, left ventricular end diastolic pressure (LVEDP) is reduced down to the normal range of about 6–12 mm Hg, during ventricular diastole of the heart.

Abstract: A method and device featuring at least one component providing a potential to kinetic converted elastic, magnetic repulsion, or, an elastic and magnetic repulsion, pushing, pulling, or, pulling and pushing, type of radially outward expansive force or pressure to an inner, outer, intermediate, and, combination thereof, wall region of the left ventricle, for reducing intraluminal hydrostatic pressure of the left ventricle (LV filling pressure) during the ventricular diastolic stage of the cardiac cycle, thereby, improving diastolic function of the left ventricle of the heart in subjects having a condition of diastolic heart failure (DHF), while minimally disturbing systolic function of the heart. The expansive force or pressure is in a range of about 5-40 mm Hg, whereby, left ventricular end diastolic pressure (LVEDP) is reduced down to the normal range of about 6-12 mm Hg, during ventricular diastole of the heart.

Abstract: The present invention provides an in vivo device for improving diastolic function of the heart, comprising: at least one elastic component that may be operatively connected to the external surface of the left or right ventricle of the heart by means of connecting elements, wherein said elastic component comprises essentially longitudinal members arranged such that the lateral separation therebetween may be increased or decreased in response to elastic deformation of said elastic component, and wherein said essentially longitudinal members are arranged such that said elastic component is curved in both the vertical and horizontal planes, such that its inner surface may be adapted to the curvature of the external ventricular surface of the heart, such that said elastic component is capable of exerting both radially outward expansive and tangentially-directed forces on the external surface of the cardiac ventricle.

Abstract: Polynucleotide expression constructs, populations of cells and methods of treating diseases caused by dysfunction in, or damage to, excitable tissues are provided.

Abstract: A method of modifying the electrophysiological function of an excitable tissue region of an individual is provided. The method includes the step of implanting cells into the excitable tissue region. Each implanted cell is (a) capable of forming gap junctions with at least one cell of the excitable tissue region; and (b) capable of forming a functional ion channel or transporter, wherein the functional ion channel or transporter is capable of modifying the electrophysiological function of the excitable tissue region.

Abstract: A method and device featuring at least one component providing a potential to kinetic converted elastic, magnetic repulsion, or, an elastic and magnetic repulsion, pushing, pulling, or, pulling and pushing, type of radially outward expansive force or pressure to an inner, outer, intermediate, and, combination thereof, wall region of the left ventricle, for reducing intraluminal hydrostatic pressure of the left ventricle (LV filling pressure) during the ventricular diastolic stage of the cardiac cycle, thereby, improving diastolic function of the left ventricle of the heart in subjects having a condition of diastolic heart failure (DHF), while minimally disturbing systolic function of the heart. The expansive force or pressure is in a range of about 5-40 mm Hg, whereby, left ventricular end diastolic pressure (LVEDP) is reduced down to the normal range of about 6-12 mm Hg, during ventricular diastole of the heart.